Bill Text: CA SB159 | 2019-2020 | Regular Session | Amended
Bill Title: HIV: preexposure and postexposure prophylaxis.
Spectrum: Moderate Partisan Bill (Democrat 6-1)
Status: (Passed) 2019-10-07 - Chaptered by Secretary of State. Chapter 532, Statutes of 2019. [SB159 Detail]
Download: California-2019-SB159-Amended.html
Amended
IN
Assembly
July 01, 2019 |
Amended
IN
Senate
May 17, 2019 |
Amended
IN
Senate
April 30, 2019 |
Amended
IN
Senate
April 11, 2019 |
Amended
IN
Senate
April 01, 2019 |
Amended
IN
Senate
February 27, 2019 |
Senate Bill | No. 159 |
Introduced by Senator Wiener (Principal coauthors: Assembly Members Gipson and Gloria) (Coauthors: Senators Glazer and Stone) (Coauthor: Assembly Member Chiu) |
January 23, 2019 |
LEGISLATIVE COUNSEL'S DIGEST
Digest Key
Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: YESBill Text
The people of the State of California do enact as follows:
SECTION 1.
Section 4052 of the Business and Professions Code is amended to read:4052.
(a) Notwithstanding any other law, a pharmacist may:SEC. 2.
Section 4052.02 is added to the Business and Professions Code, to read:4052.02.
(a) Notwithstanding any other law, a pharmacist may initiate and furnish HIV preexposure prophylaxis(2)“Postexposure prophylaxis” means either of the
following:
(A)Tenofovir disoproxil fumarate (TDF) (300 mg) with
emtricitabine (FTC) (200 mg), taken once daily, in combination with either raltegravir (400 mg), taken twice daily, or dolutegravir (50 mg), taken once daily.
(B)Tenofovir disoproxil fumarate (TDF) (300 mg) and emtricitabine (FTC) (200 mg), taken once daily, in combination with darunavir (800 mg) and ritonavir (100 mg), taken once daily.
(3)“CDC guidelines” means either of the following publications by the federal Centers for Disease Control and Prevention:
(A)“2017 Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2017 Update: A Clinical Practice Guideline.”
(B)“Updated Guidelines for Antiretroviral Postexposure Prophylaxis
After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV – United States, 2016.”
(c)
(d)
(e)A pharmacist may furnish a complete course of postexposure prophylaxis if all of the following conditions are met:
(1)The pharmacist screens the patient and determines the exposure occurred within the previous 72 hours and the patient otherwise meets the clinical criteria for postexposure prophylaxis consistent with CDC guidelines.
(2)The pharmacist provides HIV testing or determines the patient is willing to undergo HIV testing consistent with CDC guidelines. If the patient refuses to undergo HIV testing but is otherwise eligible for postexposure prophylaxis under this
section, the pharmacist may furnish postexposure prophylaxis.
(3)The pharmacist provides counseling to the patient on the use of postexposure prophylaxis consistent with CDC guidelines, which may include education about side effects, safety during pregnancy and breastfeeding, adherence to recommended dosing, and the importance of timely testing and treatment, as applicable, for HIV and sexually transmitted diseases.
(4)The pharmacist notifies the patient’s primary care provider of the postexposure prophylaxis treatment. If the patient does not have a primary care provider, or refuses consent to notify the patient’s primary care provider, the pharmacist shall provide the patient a list of physicians and surgeons, clinics, or other health care service providers to contact
regarding followup care for postexposure prophylaxis.
(5)The pharmacist does not furnish postexposure prophylaxis to a single individual more than two times in a calendar year.
SEC. 3.
Section 4052.03 is added to the Health and Safety Code, to read:4052.03.
(a) Notwithstanding any other law, a pharmacist may initiate and furnish HIV postexposure prophylaxis in accordance with this section.SEC. 3.SEC. 4.
Section 1342.74 is added to the Health and Safety Code, immediately following Section 1342.73, to read:1342.74.
(a) Notwithstanding Section 1342.71, a health care service plan shall not subject combination antiretroviral drug treatments that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or step therapy.(c)